CN1310627A - 生发/护发组合物和涉及该组合物的方法 - Google Patents
生发/护发组合物和涉及该组合物的方法 Download PDFInfo
- Publication number
- CN1310627A CN1310627A CN99808860A CN99808860A CN1310627A CN 1310627 A CN1310627 A CN 1310627A CN 99808860 A CN99808860 A CN 99808860A CN 99808860 A CN99808860 A CN 99808860A CN 1310627 A CN1310627 A CN 1310627A
- Authority
- CN
- China
- Prior art keywords
- compositions
- immunomodulatory compounds
- hair
- water
- maintenance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000003779 hair growth Effects 0.000 title claims abstract description 34
- 238000012423 maintenance Methods 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 28
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000004761 scalp Anatomy 0.000 claims description 42
- 210000004209 hair Anatomy 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 28
- 201000004384 Alopecia Diseases 0.000 claims description 27
- 231100000360 alopecia Toxicity 0.000 claims description 25
- 102000016943 Muramidase Human genes 0.000 claims description 18
- 108010014251 Muramidase Proteins 0.000 claims description 18
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 18
- 235000010335 lysozyme Nutrition 0.000 claims description 18
- 229940051921 muramidase Drugs 0.000 claims description 15
- 230000003203 everyday effect Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 8
- 229920002498 Beta-glucan Polymers 0.000 claims description 8
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 102000006992 Interferon-alpha Human genes 0.000 claims description 5
- 108010047761 Interferon-alpha Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 5
- 229920001503 Glucan Polymers 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 229920000057 Mannan Polymers 0.000 claims description 4
- 235000020694 echinacea extract Nutrition 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- 229940092782 bentonite Drugs 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229950010118 cellacefate Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 238000011161 development Methods 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 9
- 230000003676 hair loss Effects 0.000 description 8
- 239000010408 film Substances 0.000 description 7
- 201000009495 Hypotrichosis Diseases 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 101100011509 Drosophila melanogaster Baldspot gene Proteins 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000258180 Echinacea <Echinodermata> Species 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000014134 echinacea Nutrition 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000003803 hair density Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000019980 sodium acid phosphate Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical class [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
公开了生发/护发组合物。该组合物包含水、水溶性成膜聚合物和用量能有效促进生发/护发的免疫调节化合物。还公开了用于生发/护发的方法以及针对生发/护发的用途。
Description
本发明涉及生发/护发组合物和用于生发/护发的方法。更具体地说,本发明涉及用于涂到头发上,防止脱发和提供新发生长的组合物。
脱发、毛发稀疏和秃发已经成为影响全世界无数人们(包括男性和女性)的人类生活的实际情况。这些情况往往使患者感到不自然,极为窘迫。有时可以导致缺乏自信和心理障碍。
人们已经竭尽全力治疗脱发、毛发稀疏和秃发,用于治疗这些问题的大量方法就可以证明这一点。非外科的方法大多数似乎是无效的。就外科方法而论,这些操作(例如,把取自身体其它部位的毛囊植入头皮)是昂贵、不方便的而且有时是疼痛的操作。一般而言,其它外科方法也具有这些缺点。
头发稀疏的人以及有秃斑的人往往使用小撮假发。这些用具可能被认为不便佩戴,如果在佩戴过程中移位的话令人非常窘迫。这类用具可能是昂贵的而且往往具有也许不能反映佩戴者其它发色的不自然外观。当天然毛发变亮、随年龄而变灰或变白时,这一点就特别明显。
针对妇女(她们因为诸如激素变化或失调、年龄等因素而患有脱发)的组合物一般呈固发凝胶的形式。这些产品似乎从空气中吸引污物,需要经常洗发。对某些人而言,这些组合物可能还刺激头皮。
美国专利No.4,737,362(“Yoshizumi”)描述了用于加速毛发生长的滋发剂组合物,它们含有源于细菌的脂酶,即,一种似乎具有抗细菌活性的脂质降解酶。这类组合物的缺点是,引起毛发干燥、头皮瘙痒和刺激、涂到发肤上之后的令人不快的气味以及长期使用时可能对发肤/头皮的损害。
本发明解决于现有技术中的上述问题,为生发/护发提供了简单、成本低且方便的解决方案。
本发明人已经令人惊讶地发现,含有免疫调节化合物(即,已知能调节免疫系统的化合物)的组合物特别适合于刺激新毛发生长和/或保持毛发生长(防止脱发)。这些化合物以含有水和水溶性成膜聚合物的配方的形式涂敷到毛发上。
本发明的第一个方面提供了一种生发/护发组合物,它包括水、水溶性成膜聚合物和用量能有效促进生发/护发的免疫调节化合物。
本发明的另一方面提供了一种用于生发/护发的方法,该方法包括在头皮或者皮肤的其它区域涂敷一种组合物,该组合物包含水、水溶性成膜聚合物和用量能有效促进生发/护发的免疫调节化合物。
本发明的又一方面提供了已知能调节免疫系统的化合物与成膜聚合物和水一起在生产用于治疗秃发和护发的药物中的用途。
在附图中,图1至10描绘了用实施例的组合物治疗的个体的头皮,在治疗开始时和治疗之后。图1:一个45岁男子治疗前的头皮(A)和经三个月治疗之后的头皮(B)的顶视图。图2:一个67岁男子的头皮的顶视图,显示治疗前明显的秃斑。图3:图2的研究对象经三个月治疗后的头皮的侧部和顶部之上的视图。图4:志愿者001在治疗前(A)和经十个月治疗后(B)的头皮顶部的视图。图5:志愿者002在治疗前(A)、经三个月治疗后(B)和经六个月治疗后(C)的头皮后部的视图。图6:志愿者004在治疗前(A)和经三个月治疗后(B)的头皮顶视图。图7:志愿者006在治疗前(A)和经三个月治疗后(B)的头皮顶视图。图8:志愿者008在治疗前(A)和经三个月治疗后(B)的头皮顶视图。图9:志愿者009在治疗前(A)和经三个月治疗后(B)的头皮顶视图。
本发明涉及能够提供新发生长并防止脱发的组合物。这些被便利地涂敷到头皮上的组合物便于立即治疗脱发、毛发稀疏和秃发。本发明的第一个方面提供了一种生发/护发组合物,它包含水、水溶性成膜聚合物以及用量能有效促进生发/护发的免疫调节化合物。
本发明的生发/护发组合物体现了在治疗脱发、毛发稀疏和秃发方面的显著进步。该组合物一旦涂到头皮上就在头发、毛囊和头皮上形成一层薄膜,这使效果最大。所谓“生发”指的是新发生长。所谓“护发”指的是毛囊继续生出毛发而不是退化并死亡。
所述水溶性成膜聚合物可以选自一种或多种天然或合成的水溶性成膜聚合物,例如阿拉伯胶、白蛋白、琼脂、藻酸及其盐、膨润土、卡波姆、角叉藻聚糖、羧甲基纤维素及其盐、乙酸邻苯二甲酸纤维素的盐、环糊精、葡聚糖、糊精、明胶、羟乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、羟丙基甲基纤维素邻苯二甲酸酯以及其它纤维素衍生物、洋车前子(ispaghula)、卵磷脂、羊毛脂醇、麦芽糖糊精、果胶、聚维酮、聚乙烯吡咯烷酮、聚乙酸乙烯酯、淀粉、西黄蓍胶等。成膜聚合物的确切性质通常并不重要,只要它在涂到头皮上时能形成一层便利的薄膜即可。
一旦该组合物在头皮上干燥,该组合物是不引人注意的。当头皮上存在头发时,使毛发数量更多,得到更充实的外观,这也是赏心悦目的。
所述免疫调节化合物是一种能调节免疫反应[例如,减弱、强化或刺激免疫反应(体液的或细胞的免疫反应)的某些方面]的化合物,优选是免疫刺激化合物,例如,胞壁质酶(也称为溶菌酶盐酸化物或球蛋白G1)、干扰素(如α,β和γ-干扰素)、非炎性白细胞介素、胰岛素样生长因子-1(1GF-1)、表皮生长因子(EGF)、松果菊属(Echinacea)提取物、甘露聚糖、杂木聚糖(heteroxylan)、阿糖基鼠李半乳聚糖(arabinorhamnogalactan)、β-葡聚糖以及具有免疫刺激功能的其它化合物。胞壁质酶是特别优选的。这些免疫调节化合物并不诱发可能导致癌症状态的细胞转化/无限增殖化(而成纤维细胞生长因子、TFG-13、角质形成细胞生长因子等会出现这种情况)。具体排除了白细胞介素1α、白细胞介素1β、TNF-α和TNF-β,因为已发现这些蛋白质抑制生发。本发明的组合物可以包含两种或两种以上的免疫调节化合物。
本发明的组合物通常包含0.01%~10%(w/w)的免疫调节化合物,优选0.05%~1%(w/w)--当该免疫调节化合物是胞壁质酶时,它通常以约0.01%~约10%(w/w)、优选约0.05%~约1%(w/w)的量存在。当该免疫调节化合物是干扰素时,它通常以约1IU~约10,000IU的量存在。当该免疫调节化合物是β-葡聚糖时,它通常以约.01mg~约200mg/ml、优选约、优选约0.1mg~约50mg/ml的量存在。当该免疫调节化合物是非炎性白细胞介素时(这可以在实验性动物中容易地确定),例如是白细胞介素1β(163~171)时,该化合物通常以0.01mg~100mg/ml、优选0.1mg~20mg/ml的量存在。
所述免疫调节化合物可以呈本领域已知的任何药物上可接受的盐的形式,例如盐酸盐或磷酸盐。
所述水溶性成膜聚合物通常以约0.01%~10%(w/w)、优选0.05%~5%(w/w)、更优选0.1%~1%(w/w)的量存在。
本发明的组合物可以包含用于组合物(该组合物用于涂到皮肤或头皮上)中的常规载体、赋形剂、缓冲剂、防腐剂和润湿剂,例如,乙二胺四乙酸(EDTA)、葡聚糖、酸式磷酸钠、磷酸二钠、酸式磷酸钾、磷酸二钾、苯甲酸钠、羟基苯甲酸丙酯、羟基苯甲酸甲酯、缓冲化合物、盐、洗涤剂(例如月桂基硫酸钠、十二烷基硫酸钠)和乳化剂等。这类组分可以约0.01%(w/w)~约10%(w/w)的量存在。例如,洗涤剂可以约0.01%(w/w)~约5%(w/w)的量存在。
本发明的组合物可以通过直接涂敷法涂到头皮上,例如,将少量该组合物倒在头皮上或手指上,然后在头皮上或起作用的区域上擦该物质。或者,可以用常规的喷雾装置(例如空气驱动的喷雾装置或烟雾装置)喷雾该组合物,这些装置被广泛用于涂敷香水和美容制品。
该组合物中可以包含促进免疫调节化合物的稳定化的化合物,例如海藻糖(一种公知的用于该目的的糖)。
水构成本发明组合物的余量,结果形成一种各溶解组分在水中的溶液,该溶液可以容易地通过常规方式涂敷到头皮上。
优选地,本发明的组合物不含任何化学喷射剂、醇、人造着色剂或可能引起头皮刺激的化学品。但一种或多种这类组分可以不引起头皮刺激的量存在。
本发明的组合物可以每天涂敷或者每三天至少涂敷一次。通常,这种使用能在四周内防止脱发。在连续使用两个月至十二个月后通常观察到毛发恢复(即新发生长)方面的可见差异。每天使用或者每三天一次地连续使用该产品可以防止脱发并有效地促进生发。
可以按本发明治疗的对象是患有脱发、毛发稀疏和/或秃发的男人和女人。患有这类病况的动物也可以用本发明的组合物治疗。
本发明的另一方面提供了一种生发/护发的方法,它包括,在头皮或皮肤的其它区域涂敷一种组合物,该组合物包含水、水溶性成膜聚合物以及用量能有效促进生发/护发的免疫调节化合物。
在根据本发明一个方面的方法中,将上述组合物涂敷到希望发生生发/护发的头皮或皮肤区域。优选每天在头皮/皮肤上涂敷。可以把该组合物喷雾或倒在待治疗的区域上并且可以用手指轻柔地擦或者经过头发和头皮方便地进行涮洗或梳理。该组合物在头皮或皮肤上形成一层薄而不引人注意的膜,并且在存在的任何头发上形成一层薄而不引人注意的膜。该组合物给残留的所有头发提供充分而密实的感觉,这改善被治疗的人的外表,而且还防止脱发并促进生发。
如上所述,通常在治疗四周之内防止了脱发,在连续使用本发明的组合物两个月至十二个月之内通常观察到头发恢复方面的可见不同。
本发明的组合物/方法的确切作用机理尚不清楚。不想受任何作用理论的束缚,本发明人认为,所述免疫调节化合物与成膜聚合物一起,可以以一种防止脱发和刺激新发生长的方式,调节毛囊水平的免疫反应。通过延长毛囊的生长期和缩短退化期,本发明的组合物可以逆转与脱发/秃发有关的异常循环,这可以解释减缓/防止秃发/脱发过程和以天然方式进行的新发生长。
现参照下列非限制性实施例描述本发明。
实施例1制备如下配制品:
胞壁质酶 | 100mg |
明胶 | 100mg |
海藻糖 | 100mg |
EDTA二钠 | 140mg |
葡聚糖 | 250mg |
酸式磷酸钠 | 270mg |
磷酸钠 | 1160mg |
羟基苯甲酸丙酯 | 30mg |
羟基苯甲酸甲酯 | 90mg |
净化水 | 100ml |
制备了其它配制品,在这些配制品中,溶菌酶被α干扰素、β干扰素、γ干扰素、白细胞介素-1β(163-171)肽、胰岛素样生长因子-1(IGF)-1)、表皮生长因子(EGF)、松果菊属提取物、甘露聚糖、杂木聚糖、阿糖基鼠李半乳聚糖和β-葡聚糖和非炎性白细胞介素替代。所有这些免疫调节化合物都可以从药品/化学品供应商处获得。
实施例2
成年妇女K夫人开始每天脱落大量头发,并且在她头部左侧形成了一条可见的退缩发线(receding hairline),从头皮前部可以注意到。为改善这一问题,K夫人已经使用过一种非醇预喷凝胶(non-alcohol pre-spray on gel)把其头发保持在应有的位置以掩盖退缩的斑块。该产品从空气中吸污,使头发看上去没有吸引力。需要频繁洗发,这又可能导致继续脱发。制备了一种实施例1的含溶菌酶的组合物,每天将其喷到起作用的区域直至头发稍稍湿润。用梳子、刷子或者简单地用手,将稍稍润湿的头发用于在退缩区域上形成一种遮蔽。三周后,K夫人注意到脱发被显著地减少,并且在起作用区域上有短发生长增生。
实施例3
成年男子J先生从头皮的两侧开始有退缩发线,每天脱发,这已经变得非常明显。J先生开始每天在起作用区域涂敷实施例1的胞壁质酶组合物。作为对照,向右肘上喷少量该组合物,用肘的左侧作为对照。在将组合物喷在双腕上的情况下,在J先生具有很细小的短发的情况下,还进行了斑块测试,这样使任何生长都是可见的而且能够被监测。在该测试中,通过每个腕,以一个手指的宽度,将组合物擦到皮肤表面上十秒钟。两个月后,在头皮的秃斑上有引人注意的头发生长,同样,在测试斑块上可见到长而浓密的头发生长,而在对照部位上没有额外的头发生长。
每天使用该含胞壁质酸的组合物经十二个月后,K夫人和J先生不再有退缩头发的问题,可见到他们的头发恢复生长了。
实施例4
对于大约100个患有不同程度的毛发稀疏、脱发和秃发的人测试了含胞壁质酶的组合物。大多数测试对象已经发现,大约使用四周后已防止了脱发,观察到新发生长。
而且发现了,头发生长通常是本人头发的本色。如果该组合物的使用者已经是白/灰发,新发生长通常不是白/灰色头发而是头发变白/灰之前该人原来的发色。
图1显示了已经秃发十五年以上的一名45岁使用者头皮的照片。每天涂敷实施例1的组合物后,仅在使用两个月后就观察到毛囊和新发的生长,这一点在图2中很明显。
图3显示了一名67岁男子的头皮照片,在白发中有一秃斑,仅有很少的侧部生长。在涂敷实施例1的组合物三个月后,在图4中可以看到黑发的新生长,这样的头发在治疗前是不存在的。
对6个个体的探索研究的结果列于下表,所述个体每天在其头皮上涂敷含胞壁质酶的实施例1的组合物。
志愿者编号 | 性别 | 年龄 | 秃发史 | 治疗时间 | 注释 |
001 | M | 35 | 10年 | 14个月 | 覆盖整个头盖的浓密细发 |
002 | M | 46 | 20年 | 12个月 | 在头顶区域有最大改善,为秃发部位 |
004 | M | 32 | 4年 | 9个月 | 头发稀疏停止 |
006 | M | 26 | 7年 | 8个月 | 头发密度普遍提高 |
008 | M | 57 | 5年 | 8个月 | 密度普遍提高,头顶区域有最大改善 |
009 | M | 45 | 20年 | 6个月 | 头发密度普遍提高 |
经三个月治疗后所得结果示于图4-9,分别涉及志愿者001~009。这些图显示,经三个月治疗后,没有发生脱发,新发生长已经形成。用一种不含胞壁质酶和成膜聚合物的组合物治疗的对照对象(对照)是无效的。
在另一组实验中,测试了实施例1的组合物,但这些组合物中含有α干扰素、β干扰素、γ干扰素、白细胞介素-1β(163-171)肽或其它非炎性白细胞介素、胰岛素样生长因子-1(1GF-1)、松果菊属提取物、甘露聚糖、杂木聚糖、阿糖基鼠李半乳聚糖、或β-葡聚糖代替胞壁质酶。在治疗过的对象中,观察到新发生长和脱发停止,这十分令人满意。然而,比较而言,用胞壁质酶获得的结果更优越。
本发明的组合物防止脱发,也就是说,提供毛发护理并提供新发生长。
本领域技术人员能够理解,这里描述的本发明除了那些具体描述的以外还可以有各种改变和改进。应理解的是,本发明包括那些落在本发明实质和范围之内的所有这类改变和改进。本发明还包括本说明书中引用或指出的所有步骤、特征、组合物和化合物(单独地或整体地),或者任何两个或两个以上所述步骤或特征的任意和所有组合。
本说明书全文中,除非上下文中另有要求,用语“包含”或其变体或者术语“包括”或其变体应理解为是指,包括所述要素或整数或者这些要素或整数的组,但不排除任何其它要素或整数或者这些要素或整数的组。在这方面,在确定权利要求范围时,一个实施方案(在一个或多个特征被加到任一权利要求中的情况下)要被视为在本发明的范围之内,只要所要求保护的本发明的基本特征包含在这个实施方案中即可。
Claims (13)
1.一种生发/护发组合物,它包含水、水溶性成膜聚合物以及用量能有效促进生发/护发的免疫调节化合物。
2.根据权利要求1的组合物,其中所述免疫调节化合物选自胞壁质酶、干扰素、非炎性白细胞介素、胰岛素样生长因子-1(1GF-1)、表皮生长因子(EGF)、松果菊属提取物、甘露聚糖、杂木聚糖、阿糖基鼠李半乳聚糖或β-葡聚糖。
3.根据权利要求2的组合物,其中所述免疫调节化合物是胞壁质酶、α干扰素、β干扰素、γ干扰素、白细胞介素-1β(163-171)肽或β-葡聚糖。
4.根据权利要求2的组合物,其中所述免疫调节化合物是胞壁质酶。
5.根据权利要求1的组合物,它包含两种或两种以上的免疫调节化合物。
6.根据权利要求1的组合物,其中所述水溶性成膜聚合物选自天然或合成的水溶性成膜聚合物,它们包括:阿拉伯胶、白蛋白、琼脂、藻酸及其盐、膨润土、卡波姆、角叉藻聚糖、羧甲基纤维素及其盐、乙酸邻苯二甲酸纤维素的盐、环糊精、葡聚糖、糊精、明胶、羟乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、羟丙基甲基纤维素邻苯二甲酸酯以及其它纤维素衍生物、洋车前子、卵磷脂、羊毛脂醇、麦芽糖糊精、果胶、聚维酮、聚乙烯吡咯烷酮、聚乙酸乙烯酯、淀粉和西黄蓍胶。
7.一种生发/护发的方法,它包括,在头皮或皮肤的其它区域涂敷一种组合物,该组合物包含水、水溶性成膜聚合物以及用量能有效促进生发/护发的免疫调节化合物。
8.根据权利要求7的方法,其中所述免疫调节化合物选自胞壁质酶、干扰素、非炎性白细胞介素、胰岛素样生长因子-1(IGF-1)、表皮生长因子(EGF)、松果菊属提取物、甘露聚糖、杂木聚糖、阿糖基鼠李半乳聚糖或β-葡聚糖。
9.根据权利要求7的方法,其中所述免疫调节化合物是α干扰素、β干扰素、γ干扰素、白细胞介素-1β(163-171)肽或β-葡聚糖。
10.根据权利要求7的方法,它包含两种或两种以上的免疫调节化合物。
11.根据权利要求7的方法,其中所述免疫调节化合物是胞壁质酶。
12.根据权利要求7的方法,其中将所述组合物每天或者至少每三天一次地局部涂敷到头皮上。
13.已知能调节免疫系统的化合物与成膜聚合物和水一起在生产用于治疗秃发和护发的药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP4897 | 1998-07-28 | ||
AUPP4897A AUPP489798A0 (en) | 1998-07-28 | 1998-07-28 | Hair growth/maintenance compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1310627A true CN1310627A (zh) | 2001-08-29 |
Family
ID=3809133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99808860A Pending CN1310627A (zh) | 1998-07-28 | 1999-07-28 | 生发/护发组合物和涉及该组合物的方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1102598A1 (zh) |
JP (1) | JP2002521457A (zh) |
CN (1) | CN1310627A (zh) |
AU (1) | AUPP489798A0 (zh) |
CA (1) | CA2338797A1 (zh) |
WO (1) | WO2000006188A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772790A (zh) * | 2012-06-28 | 2012-11-14 | 齐鲁动物保健品有限公司 | 一种复方紫锥菊制剂及其制备方法和应用 |
CN102988195A (zh) * | 2012-12-10 | 2013-03-27 | 北京莱米瑞克科技发展有限公司 | 脂质体防脱发制剂 |
CN102988196A (zh) * | 2012-12-10 | 2013-03-27 | 北京莱米瑞克科技发展有限公司 | 脂质体生发制剂 |
CN106492196A (zh) * | 2016-11-16 | 2017-03-15 | 南宁学院 | 一种母猪用免疫增强剂 |
CN109106645A (zh) * | 2018-09-28 | 2019-01-01 | 袁浩卿 | 一种洗发水 |
WO2020001314A1 (zh) * | 2018-06-26 | 2020-01-02 | 浙江立恩生物科技有限公司 | 具有生发固发防脱效果的生物多糖及其应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054673A1 (en) * | 2000-01-31 | 2001-08-02 | The University Of British Columbia | Method for preparing and administering medicinal plant material |
KR100499564B1 (ko) * | 2003-03-28 | 2005-07-07 | 신석봉 | 모발의 재생방법 및 발모제 조성물 |
WO2005063279A1 (en) * | 2003-12-29 | 2005-07-14 | Universitätsklinikum Münster | Means for stimulation and activation of hair growth by il-15 |
US20080124408A1 (en) | 2004-07-07 | 2008-05-29 | Mediherb Holdings Ltd. | Echinacea Formulation |
DE102005031705A1 (de) * | 2005-07-05 | 2007-01-18 | Henkel Kgaa | Mittel, enthaltend L-Carnitin oder L-Carnitinderivate und mindestens eine weitere Substanz ausgewählt aus Taurin und dessen Derivaten und mindestens einem Wirkstoff, erhältlich aus Pflanzen der Gattung Echinacea |
JP2008127313A (ja) * | 2006-11-20 | 2008-06-05 | Japan Natural Laboratory Co Ltd | Egfを配合してなる化粧料および毛髪料 |
DE102009044973A1 (de) | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Verwendung eines Wirkstoffes aus Echinacea zur Beeinflussung des natürlichen Pigmentierungsprozesses |
CN102716164B (zh) * | 2012-06-28 | 2014-11-12 | 齐鲁动物保健品有限公司 | 一种紫锥菊提取物及其制备方法 |
CN103918700B (zh) * | 2014-03-28 | 2016-02-24 | 海南力智生物工程有限责任公司 | 一种杀虫颗粒及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS615006A (ja) * | 1984-06-19 | 1986-01-10 | Sanki Shoji Kk | 皮膚用剤 |
US4839164A (en) * | 1987-02-24 | 1989-06-13 | Estee Lauder, Inc. | Trehalose containing cosmetic composition and method of using it |
US5616471A (en) * | 1987-05-06 | 1997-04-01 | The United States Of America As Represented By The Department Of Health And Human Services | Effects of growth factors on hair follicle cell proliferation and release of collagenolytic factors |
GB8806893D0 (en) * | 1988-03-23 | 1988-04-27 | Unilever Plc | Cosmetic composition |
US5599558A (en) * | 1989-09-15 | 1997-02-04 | Curative Technologies, Inc. | Selecting amounts of platelet releasate for efficacious treatment of tissue |
PT100638B (pt) * | 1991-06-28 | 1999-09-30 | Univ Miami | Metodo para evitar e tratar a alopecia induzida por quimioterapia |
JPH05213720A (ja) * | 1992-02-05 | 1993-08-24 | Sansho Seiyaku Co Ltd | 毛髪用外用剤 |
DZ1964A1 (fr) * | 1995-01-13 | 2002-10-15 | Nika Health Products Ltd | Nouvelle applications d'un dimère de lysozyme. |
JP3593193B2 (ja) * | 1995-11-14 | 2004-11-24 | 大日本製薬株式会社 | 養毛料 |
WO1997038002A1 (en) * | 1996-04-10 | 1997-10-16 | Human Genome Sciences, Inc. | Extracellular/epidermal growth factor-like protein |
-
1998
- 1998-07-28 AU AUPP4897A patent/AUPP489798A0/en not_active Abandoned
-
1999
- 1999-07-28 WO PCT/AU1999/000607 patent/WO2000006188A1/en not_active Application Discontinuation
- 1999-07-28 CN CN99808860A patent/CN1310627A/zh active Pending
- 1999-07-28 JP JP2000562042A patent/JP2002521457A/ja active Pending
- 1999-07-28 EP EP99932566A patent/EP1102598A1/en not_active Withdrawn
- 1999-07-28 CA CA002338797A patent/CA2338797A1/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772790A (zh) * | 2012-06-28 | 2012-11-14 | 齐鲁动物保健品有限公司 | 一种复方紫锥菊制剂及其制备方法和应用 |
CN102772790B (zh) * | 2012-06-28 | 2014-08-06 | 齐鲁动物保健品有限公司 | 一种复方紫锥菊制剂及其制备方法和应用 |
CN102988195A (zh) * | 2012-12-10 | 2013-03-27 | 北京莱米瑞克科技发展有限公司 | 脂质体防脱发制剂 |
CN102988196A (zh) * | 2012-12-10 | 2013-03-27 | 北京莱米瑞克科技发展有限公司 | 脂质体生发制剂 |
CN102988195B (zh) * | 2012-12-10 | 2014-12-10 | 北京莱米瑞克科技发展有限公司 | 脂质体防脱发制剂 |
CN106492196A (zh) * | 2016-11-16 | 2017-03-15 | 南宁学院 | 一种母猪用免疫增强剂 |
WO2020001314A1 (zh) * | 2018-06-26 | 2020-01-02 | 浙江立恩生物科技有限公司 | 具有生发固发防脱效果的生物多糖及其应用 |
CN109106645A (zh) * | 2018-09-28 | 2019-01-01 | 袁浩卿 | 一种洗发水 |
Also Published As
Publication number | Publication date |
---|---|
JP2002521457A (ja) | 2002-07-16 |
CA2338797A1 (en) | 2000-02-10 |
WO2000006188A1 (en) | 2000-02-10 |
EP1102598A1 (en) | 2001-05-30 |
AUPP489798A0 (en) | 1998-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1310627A (zh) | 生发/护发组合物和涉及该组合物的方法 | |
US6419913B1 (en) | Topical delivery systems for active agents | |
US4814351A (en) | Scalp treatment | |
JPH0771571B2 (ja) | 人の外部上皮治療用用具の製造方法 | |
JPH09504021A (ja) | プロスタグランジンの新規使用 | |
AR012237A1 (es) | Composicion de depuracion antimicrobiana enjuagable y metodos para reducir la cantidad de germenes en la piel y para tratar acne. | |
US5730965A (en) | Shampoo for treating seborrheic dermatitis, dandruff or psoriasis | |
EP2802331B1 (en) | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists | |
CA2213481A1 (en) | Compositions and methods for enhancing the growth of hair and restoring hair color | |
ATE482230T1 (de) | Peptide, die bei der linderung von hautleiden oder der behandlung von periodentalkrankheiten wirkung zeigen | |
EP0854700B1 (fr) | Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute | |
US8758733B2 (en) | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists | |
KR100264051B1 (ko) | 머리카락 모세포 활성화제 및 머리카락 모세포 활성화방법 | |
JP7483331B2 (ja) | 光及びグルコサミン塩酸塩を使用して皮膚状態を治療するための組成物及び方法 | |
US9216183B2 (en) | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists | |
US8080524B2 (en) | Agent for slowing hair loss and/or stimulating hair growth | |
KR100828379B1 (ko) | 효소를 이용한 두발용 화장품 조성물 | |
CN108272781B (zh) | 豆蔻明在制备防治脱发的药物中的应用 | |
JP2022184908A (ja) | 細胞膜結合シグナル伝達因子の使用 | |
Chuang et al. | Effect of sodium lauryl sulfate (SLS) on primary human gingival fibroblasts in an in vitro wound healing model | |
JP3805914B2 (ja) | 毛穴収縮剤 | |
AU4891299A (en) | Hair growth/maintenance compositions and methods involving the same | |
JP3640727B2 (ja) | 重ね塗り式発毛剤及び、発毛方法 | |
JP2003012446A (ja) | スベリヒユ科植物抽出物を含む刺激性が低減された組成物 | |
DE3147727C2 (de) | Wundheilmittel enthaltend Kollagen aus Basalmembranen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |